Akebia Therapeutics

$3.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.22 (+7.14%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell AKBA and other stocks, options, and ETFs commission-free!

About AKBA

Akebia Therapeutics, Inc. Common Stock, also called Akebia Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA. The listed name for AKBA is Akebia Therapeutics, Inc. Common Stock.

CEO
John P. Butler
Employees
360
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
476.98M
Price-Earnings Ratio
Dividend Yield
Average Volume
5.12M
High Today
$3.32
Low Today
$3.09
Open Price
$3.10
Volume
3.79M
52 Week High
$13.71
52 Week Low
$2.09

Collections

AKBA Earnings

-$0.79
-$0.53
-$0.26
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 9, Pre-Market

You May Also Like